Sandy Blauvelt News Today

Blauvelt discusses the future research of higher-dose risankizumab for patients with psoriasis—and why it may be "disruptive in the treatment space."

Blauvelt discusses the impetus for his phase 2 trial looking at the ability to mitigate pivotal psoriasis memory T cells with risankizumab.

Expert dermatologists highlight the benefits of head-to-head trials for various agents for the management of plaque psoriasis and review the top-line results of a study comparing risankizumab and apremilast.

The city's 2005 "citizen of the year" honoree was an adviser in local politics and a former Board of Supervisors aide.

Andy Blauvelt, MD, MBA, president of Oregon Medical Research Center, discusses challenges many physicians face in getting approved for the most effective drugs to treat patients with atopic dermatitis (AD).

If there’s one thing about Tarrant County’s unincorporated areas, it’s that there are few rules, and the ones that do exist are hard to enforce.

Andy Blauvelt, MD, MBA, president of Oregon Medical Research Center, discusses the use of systemic therapies vs biologics and why adherence is so important when treating patients with atopic dermatitis (AD).

Andrew Blauvelt, MD, leads a roundtable discussion with Melinda Gooderham, MSc, MD, and Neil Korman, MD

Andrew Blauvelt, MD, leads a discussion with Melinda Gooderham, MD, MSc, and Neil Korman, MD, PhD

An expert roundtable discussion on guselkumab and risankizumab